Brainstorm Cell Therapeutics(BCLI) - 2025 Q1 - Quarterly Results

Financial Performance - As of March 31, 2025, cash, cash equivalents, and restricted cash totaled approximately $1.8 million[7] - Research and development expenditures for Q1 2025 were $1.3 million, up from $1.0 million in Q1 2024, representing a 30% increase[7] - General and administrative expenses for Q1 2025 were approximately $1.8 million, compared to approximately $1.5 million in Q1 2024, reflecting a 20% increase[7] - The net loss for Q1 2025 was approximately $2.9 million, an improvement from a net loss of approximately $3.4 million in Q1 2024, indicating a 15% reduction in losses[7] - Net loss per share for Q1 2025 was $0.45, compared to $0.75 for Q1 2024, showing a 40% improvement[7] Clinical Trials and Research - The planned Phase 3b clinical trial for NurOwn is designed to enroll approximately 200 early-stage ALS participants[3] - An IND amendment for NurOwn has been submitted to the FDA, marking a significant milestone for the upcoming Phase 3b trial[3] - NurOwn data was selected for presentation at the ISCT 2025 Meeting, highlighting the impact of the UNC13A genotype on clinical outcomes for ALS patients[3] Assets and Liabilities - Total assets as of March 31, 2025, were $3.571 million, compared to $1.832 million as of December 31, 2024, indicating a significant increase[15] - Total liabilities as of March 31, 2025, were $11.028 million, up from $9.596 million as of December 31, 2024[15]